gorodenkoff
Cantor Fitzgerald started coverage of Krystal Biotech (NASDAQ:KRYS) with an overweight rating, citing the company’s launch for its drug Vyjuvek.
The investment bank said it expects Vyjuvek to have a “very strong launch,” with potential peak worldwide sales of more than $1B. The drug is used to treat a genetic blistering disease called Dystrophic Epidermolysis Bullosa, or DEB.
Cantor noted that its sales estimates for Vyjuvek in 2024 are around $220M, significantly above its cited consensus estimate of $163M, adding that its estimates may “prove to be conservative if the early launch metrics are sustained.”
The bank set its price target for the stock at $160.
